Although kisspeptin is the primary stimulator of gonadotropin-releasing hormone secretion and therefore the hypothalamic-pituitary-gonadal axis, recent findings suggest kisspeptin can also regulate additional neuroendocrine processes including release of growth hormone (GH). Here we show that central delivery of kisspeptin causes a robust rise in plasma GH in fasted but not fed sheep. Kisspeptin-induced GH secretion was similar in animals fasted for 24 hours and those fasted for 72 hours, suggesting that the factors involved in kisspeptin-induced GH secretion are responsive to loss of food availability and not the result of severe negative energy balance. Pretreatment with the neuropeptide Y (NPY) Y1 receptor antagonist, BIBO 3304, blocked the effects of kisspeptin-induced GH release, implicating NPY as an intermediary. Kisspeptin treatment induced c-Fos in NPY and GH-releasing hormone (GHRH) cells of the arcuate nucleus. The same kisspeptin treatment resulted in a reduction in c-Fos in somatostatin (SS) cells in the periventricular nucleus. Finally, blockade of systemic ghrelin release or antagonism of the ghrelin receptor eliminated or reduced the ability of kisspeptin to induce GH release, suggesting the presence of ghrelin is required for kisspeptin-induced GH release in fasted animals. Our findings support the hypothesis that during shortterm fasting, systemic ghrelin concentrations and NPY expression in the arcuate nucleus rise. This permits kisspeptin activation of NPY cells. In turn, NPY stimulates GHRH cells and inhibits SS cells, resulting in GH release. We propose a mechanism by which kisspeptin conveys reproductive and hormone status onto the somatotropic axis, resulting in alterations in GH release. (Endocrinology 158: 3526-3539, 2017) K isspeptin is the most potent known stimulator of gonadotropin-releasing hormone (GnRH). The distribution, gonadal hormone regulation, and developmental activity of kisspeptin neurons in the hypothalamus implicate kisspeptin as a major player in the control of the hypothalamic-pituitary-gonadal axis (1). Although the role for kisspeptin as a stimulator of GnRH is undisputed, it may also play a role in regulation of additional neuroendocrine processes including the release of growth hormone (GH). We have demonstrated previously that central, but not peripheral, delivery of kisspeptin causes a robust release of GH in sheep (2). However, the neural mechanism linking central kisspeptin delivery and GH release remains unclear. Subsequent
studies reported that kisspeptin immunopositive fibers are in close apposition to neuropeptide Y (NPY) cells in the arcuate nucleus, NPY cells of the arcuate nucleus express the kisspeptin receptor [GPR54 (also known as KISSR1)], and central infusion of kisspeptin increases NPY expression in these species (3, 4) . As with kisspeptin, central NPY treatment is known to stimulate GH release in sheep (5, 6) . NPY stimulates GH release by activating GH-releasing hormone (GHRH) neurons in the arcuate nucleus and inhibiting somatostatin (SS) cells found in found in the periventricular nucleus of the hypothalamus (6) (7) (8) (9) (10) (11) (12) (13) . The GHRH and SS neuroendocrine cells project to the external zone of the median eminence and GHRH and SS are secreted into the hypophyseal portal circulation to act upon the pituitary somatotropes to, respectively, stimulate or inhibit GH release (8, (14) (15) (16) .
Kisspeptin reliably induces GH secretion in short-term fasted but not fed animals when centrally administered. Using pharmacological and neuroanatomical techniques, the current study provides evidence that NPY and ghrelin are involved in the stimulation of GH secretion by kisspeptin. Thus, kisspeptin stimulates NPY neurons in the arcuate nucleus, resulting in stimulation of GHRH cells and inhibition of SS cells and leading to increased GH plasma levels. Finally, we present evidence that gutderived ghrelin is required for kisspeptin-induced GH release. These findings support the existence of a neural bridge between a pivotal reproductive factor, kisspeptin, and mediators of GH release. Accordingly, kisspeptin cells may have a dual function to regulate both reproduction and metabolic homeostasis. Sheep were chosen as the preferred model system because the regulation of GH has been shown to be similar to that of humans, particularly during times of short-term fasting (15, (17) (18) (19) (20) (21) (22) . In ruminants, which are agriculturally important, growth physiology has been extensively studied, especially the interrelationship between nutrition and somatic growth with endocrine hormones and peptide growth factors.
Materials and Methods
All animal protocols were reviewed and approved by the Auburn University Institutional Animal Care and Use Committee. Mature female Suffolk mixed-breed sheep were obtained from local producers and were administered Panacur ® (Merck Animal Health, Madison, NJ) and CORID ® (Merial, Duluth, GA) to remove internal parasites and were given a prophylactic dose of penicillin. One week before placement of intracerebroventricular (ICV) cannulas, sheep were moved to indoor raised floor pens, two animals per room, in a facility where temperature (24°C) and photoperiod (12 hours of light) were controlled. Sheep were fed a maintenance diet of 2.5% to 3% of body weight/d to maintain body weight with 14% protein. This was calculated to meet 100% of daily requirements for the duration of the experiment and water was provided ad libitum.
The animals were fasted for a day before surgery to insert ICV cannulas (2) . Anesthesia was induced with triple drip at 1.1 mL/kg (0.01% xylazine, 0.1% ketamine, and 5% guaifenesin) and maintained with isoflurane. A semicircular incision #10 cm in diameter was made in the skin on the midline of the cranium over the parietal bones (over Bregma) allowing the scalp to reflect caudally. A burr hole was made in the parietal bone 15 mm caudal to Bregma and 6 mm right of midline. A stainlesssteel Tuohy needle was advanced (the needle aperture was maintained in a rostral-dorsal orientation) at an angle of 15°to vertical and 20 to 25 mm below the surface of the skull with the aid of a sheep stereotaxic device (David Kopf Instruments, Tujunga, CA). Entry into the lateral ventricular space was confirmed by flow of cerebrospinal fluid. A vascular access port and catheter (catalog no. CP-100-4IS; Norfolk Vet Products, Skokie, IL) was used to chronically catheterize the lateral ventricle through the Touhy needle. The catheter was 4-French [0.6 mm 3 1.2 mm (inner diameter 3 outer diameter)] silicone with multiple fenestrations on the distal 15 mm and was advanced 25 mm into the ventricle, the Touhy needle was withdrawn, and the proximal end of the catheter was secured to the port, which was placed subcutaneously near the external occipital protuberance. Animals were allowed to recover from surgery for 2 weeks.
Effect of fasting on kisspeptin-induced GH
To determine the effects of fasting on kisspeptin-induce GH release, sheep (n = 6) were either fed or fasted for 24 hours before ICV kisspeptin (human kisspeptin 45-54, Kp-10, 4389-v; Peptide Institute Inc., Osaka, Japan) or saline injection. On the morning before the experiment, one-half of the sheep had any residual feed removed at 1000 hours. Also on the day before an experiment, all sheep received a jugular venous catheter, which was opened at 7:30 AM the following day and the sheep were left undisturbed until sampling. Blood samples (3 mL) were collected at 10-minute intervals from 220 to 70 minutes after ICV injection of Kp-10 (200 pmol/kg/body weight (bw) in 150 mL, flushed in with 200 mL saline) or an equivalent volume of saline at 1000 hours. Kisspeptin concentration and delivery method was determined from previous work to produce reproducible induction of GH release in the ewe (2, 23) . Blood was collected in tubes containing EDTA, centrifuged, and plasma stored for assay of free fatty acids (FFAs) and GH.
Effect of fasting 24 vs 72 hours on kisspeptin-induced GH
sheep were fasted for 24 hours to maximize the GH response to Kp-10. Sheep (n = 6) were infused with saline or BIBO 3304 (25 or 50 mg in 150 mL and flushed in with 200 mL saline, ICV) or an equivalent volume of saline at 260 and again at 215 minutes relative to time 0, at which time sheep received an ICV injection of either saline or Kp-10 (200 pmol/kg/bw). Blood samples were collected at 10-minute intervals from 260 minutes before Kp-10 to 70 minutes after Kp-10 injection (time 0). Blood was placed into EDTA tubes and centrifuged. Plasma was stored for later assay of FFA and GH.
Dual immunofluorescence for c-Fos and SS or GHRH or NPY in Kp-10-treated animals
To determine proportion of cell types demonstrating a marker of cellular activation after Kp-10 treatment in fasted animals, sheep (n = 10) received ICV cannula for infusion. Animals were fasted for 24 hours and received a jugular catheter the day before perfusion. One hour before perfusion, either saline or Kp-10 (200 pmol/kg/bw) was injected through the ICV cannula. Approximately 15 minutes before perfusion, each animal received 25,000 U of heparin via jugular catheter. The animals were euthanized with pentobarbital, decapitated, and the heads were perfused with 6 L of fixative [4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS) containing 0.1% sodium nitrite, pH 7.4] via the carotids with basilar arteries clamped off. After perfusion, the brains were removed, the hypothalamus dissected (1 cm rostral to the optic chiasm, 2 to 3 mm caudal to mammillary bodies, 2 cm laterally, just dorsal to septal nuclei). The tissue blocks were placed into fresh fixative for an additional 24 hours at 4°C. On the following day, brains were transferred to 30% sucrose (4°C) until infiltrated. Tissue was frozen and cut at a thickness of 50 mm on a cryostat in a series of six. Brain sections were placed in cryopreservative and stored at 220°C until processing.
Immunofluorescence procedures were carried out on freefloating sections at room temperature using previously published protocols (24) . Sections were washed in 0.1 M PBS to remove cryopreservative. After washing, the sections were incubated in PBS containing 3% normal donkey serum (ICN Biochemical, Costa Mesa, CA) and 0.3% Triton X-100 (SigmaAldrich, St. Louis, MO) for 1 hour. Sections were then in- A single individual, blind to treatment, performed image analysis. Fluorescent images were captured using a Nikon A1 confocal microscope system. Cells were considered double labeled only if a ring of NPY, GHRH, or SS positive cytoplasm completely surrounded a c-Fos-ir nucleus through multiple planes of focus.
Effects of atropine on kisspeptin-induced GH
The cholinergic antagonist, atropine, was used to determine whether blockade of peripheral cholinergic receptors and therefore the release of gut ghrelin could interfere with the effects of Kp-10 on GH release. Sheep (n = 6) had ICV cannulas placed at least 2 weeks before experiment day and jugular catheters were inserted 1 day before experiment day. All sheep were fasted for 24 hours. Blood was collected at 220 and 210 minutes and at 10-minute intervals for 70 minutes following injection of saline or Kp-10. Atropine (0.2 mg/kg/bw; Sparhawk Laboratories, Inc., Lenexa, KS) or saline was injected via the jugular vein immediately after the 210 minute blood sample. After the sample taken at time 0, either saline or Kp-10 (200 pmol/kg/bw) was injected through the ICV cannula. Blood was centrifuged and plasma collected and stored frozen for later assay of GH.
Effects of D-Lys3-GHRP-6 on kisspeptin-induced GH
The ghrelin antagonist, D-Lys3-GHRP-6, was used to determine whether blockade of central and peripheral ghrelin receptors could interfere with the effects of Kp-10 on GH (25) . D-Lys3-GHRP-6 is a GHS-R1a receptor antagonist [halfmaximal inhibitory concentration (IC 50 ) = 0.9 mM]. Sheep (n = 5) used previously in the atropine experiment had a jugular catheter placed the day before sampling. Sheep, fitted with an ICV cannula and jugular catheter, were fasted for 24 hours. Blood was collected at 220 and 210 minutes and at 10-minute intervals for 70 minutes following injection of saline or Kp-10. D-Lys3-GHRP-6 (70 nmol/kg/bw; Tocris Biosciences, Minneapolis, MN) or saline was injected via the jugular vein immediately after the 210 minute blood sample. After the 0-minute time point, either saline or Kp-10 (200 pmol/kg/bw) was infused through the ICV cannula. Plasma was collected and stored frozen for later assay of GH and ghrelin.
Based on the results of the first trial with the ghrelin antagonist, the study was repeated using another group of sheep and at a higher antagonist dose. Sheep (n = 5) not previously used had ICV cannulas placed 3 weeks before this experiment and a jugular catheter placed the day before sampling. Sheep were again fasted for 24 hours. Blood was collected at 220 and 210 minutes and at 10-minute intervals for 70 minutes following injection of saline or Kp-10. D-Lys3-GHRP-6 (129 nmol/kg/bw) or saline was injected via jugular vein immediately after the 210-minute blood sample. After time 0, either saline or Kp-10 (200 pmol/kg/bw) was injected through the ICV cannula. Blood was centrifuged and plasma collected and stored frozen for later GH assay.
Assays
FFA was assayed by colorimetric assay (detection limit = 0.1 mEq/L; WAKO Chemicals, Richmond, VA (26) . The coefficient of variation for both the intra-assay and interassay was ,10%. For fed vs fasted, 24 vs 72 hour fast, and BIBO 3304 experiments, GH was assayed by double antibody radioimmunoassay using materials supplied by the National Hormone and Pituitary Program of the National Institute of Diabetes and Digestive and Kidney Diseases as previously described (27, 28) . The intra-and interassay coefficients of variance for the assays were 8.25 and 12.0, respectively. GH assays for the atropine and D-Lys3-GHRP-6 experiments were assayed at the US Department of Agriculture, Beltsville, MD. The intra-assay and interassay coefficients of variation were 6.8 and 7.6, respectively. Plasma ghrelin was quantified with a commercially available ghrelin radioimmunoassay kit (active Ghrelin Kit GHRA-88HK; EMD Millipore, Billerica, MA) previously validated for sheep (29) , detection limit 7.8 pg/mL. The intra-assay and interassay coefficients of variation were ,10% for both assays.
Statistics
Plasma concentrations data were subjected to two-way analysis of variance (ANOVA) with repeated measures. If a significant (P , 0.05) interaction was detected, means comparison was preformed using Bonferroni multiple comparisons. Mean area under the curve (AUC) and peak plasma levels were determined by one-way ANOVA. Mean proportion of c-Fos-ir cells in Kp-10-and saline-treated groups was assessed by Student t test. Prism 5 for Mac was used for all analysis (GraphPad Software, Inc., La Jolla, CA)
Results

Effect of fasting on kisspeptin-induced GH
Plasma GH levels were greater in 24-hour fasted animals injected with Kp-10 (200 pmol/kg/bw) than in saline-infused fed or fasted animals at 20 through 40 minutes after treatment. Plasma GH concentrations of fasted plus Kp-10 animals were also elevated above fed plus Kp-10 animals at 20 and 30 minutes after injection. Similarly, Kp-10 infusion resulted in higher AUC and peak plasma GH hormone levels in fasted but not fed animals ( Fig. 1B and 1C ) above vehicle control animals. Independent of Kp-10 treatment, fasted animals had slightly higher GH plasma concentrations than fed animals at both the 215-(fed 0.68 vs fasted 1.92 ng/mL) and 0-(fed 0.64 vs fasted 1.93 ng/mL) minute time points before Kp-10 treatment. FFA levels were increased in fasted animals (Supplemental Fig. 1 ). However, Kp-10 had no effect on FFA levels in either fed or fasted groups.
Effect of fasting 24 vs 72 hours on kisspeptin-induced GH
Animals were food deprived for 24 or 72 hours before given a central infusion of either saline or Kp-10 (200 pmol/kg/bw). The injection of Kp-10 increased GH plasma concentrations in both fasted groups of sheep ( Fig. 2A) . Both Kp-10 groups (24 and 72 hours fasting) displayed elevated GH plasma levels above corresponding saline-infused fasted animals at 30 and 40 minutes posttreatment. At no time were plasma GH levels different between 24 hours fasted plus Kp-10 and 72 hours fasted plus Kp-10. Likewise, AUC and peak GH levels were higher in both Kp-10-treated groups compared with saline-treated animals. There were no differences in the effects of treatment between sheep fasted for 24 vs 72 hours (Fig. 2B and 2C) . FFA was elevated in 72-hour fasted animals compared with 24-hour fasted animals (Supplemental Fig. 2A and 2B ), but there was no effect of Kp-10 treatment on FFA levels.
Effects of BIBO 3304 on kisspeptin-induced GH
Animals were food-deprived for 24 hours before being given 2 central infusions of either saline or BIBO 3304 (25 or 50 mg/animal) at 260 minutes and again at 215 minutes relative to time 0, at which time sheep were infused with either saline or Kp-10 (200 pmol/kg BW) via ICV. There was a significant effect of Kp-10 on GH concentrations in 24-hour fasted sheep. Plasma GH hormone levels in the saline plus Kp-10 group were elevated above animals not receiving Kp-10 at the 20-, 30-, and 40-minute time points (Fig. 3A) . In addition, animals pretreated with 25 or 50 mg of BIBO 3304 before Kp-10 displayed lower GH levels than the saline plus Kp-10 groups at the 20 to 30 minute and 20 to 40 minute time points, respectively. Animals pretreated with 25 mg BIBO 3304 followed by Kp-10 had elevated GH concentrations at 40, 50, and 60 minutes compared with 25 mg BIBO Histograms depicting (B) AUC and (C) peak plasma GH concentration in saline or Kp-10-treated animals in fed or 24-hour fasted states. Data presented as the mean 6 standard error of the mean. Asterisks indicate statistical significance after two-way ANOVA (P , 0.05). *Significantly different from fed and fasted saline-treated groups. **Significantly different from fed plus Kp-10-treated and fed and fasted plus saline groups. Letters denote significant differences between groups (P , 0.05).
3304 plus saline animals. Plasma GH concentrations in animals pretreated with 50 mg BIBO 3304 followed by Kp-10 were no different from animals pretreated with 50 mg BIBO 3304 followed by saline. Neither dose of BIBO 3304 followed by saline had a measurable effect on GH levels when compared with saline-only infused animals. The AUC and peak plasma GH levels were significantly elevated in saline plus Kp-10 and 25 mg BIBO 3304 plus Kp-10 compared with levels in saline plus saline and 25 mg BIBO 3304 plus Kp-10, respectively ( Fig. 3B and 3C ). There were no differences in either measure (AUC or peak GH) between 50 mg BIBO plus saline and 50 mg BIBO 3304 plus Kp-10 ( Fig. 3B and 3C) .
There was no effect of Kp-10 treatment on FFA levels, regardless of BIBO 3304 or saline treatment (Supplemental Fig. 3A-3C ). When Kp-10 treatment was removed as a factor and saline or BIBO 3304 pretreatment groups were merged, animals receiving 50 mg of BIBO 3304 presented with higher AUC and peak FFA levels when compared with saline pretreated animals (Supplemental Fig. 3D and 3E ).
Dual Immunofluorescence for c-Fos and SS or GHRH or NPY
Comparisons were made in animals fasted for 24 hours that received Kp-10 or saline, of the proportions of NPY, SS, or GHRH immunofluorescent neurons, which were also c-Fos immunofluorescent. In animals treated with Kp-10, approximately 40% more NPY-ir cells colocalized with c-Fos than saline-treated animals ( Fig. 4A-4C ). Animals treated with Kp-10 had .50% fewer SS cells colocalized with c-Fos than saline-treated animals ( Fig. 4D-4F ) in the periventricular nucleus. In animals treated with Kp-10, c-Fos was observed in approximately 30% more GHRH cells than saline-treated animals ( Fig. 4G-4I ). 
Effects of atropine on kisspeptin-induced GH
The cholinergic receptor antagonist, atropine, was given to inhibit peripheral ghrelin release from the gut in animals fasted for 24 hours. Pretreatment with atropine prevented Kp-10-induced GH release (Fig. 5A ). Atropine and saline had no effect on GH concentrations. As shown previously, treatment with Kp-10 alone elevated plasma GH concentrations higher than in saline controls at 20, 30, and 40 minutes after injection. Plasma GH concentrations were greater in saline plus Kp-10-treated sheep than in atropine plus Kp-10 sheep at 20 and 30 minutes after Kp-10 treatment. Animals treated with Kp-10 alone displayed a higher AUC for GH levels than saline-treated controls (Fig. 5B) , but when pretreated with atropine, the AUC for GH levels of Kp-10-treated animals was similar to those of saline-treated animals. Peak GH levels were higher in Kp-10-treated animals than in saline controls and in animals given atropine before Kp-10 (Fig. 5C ).
Effects of D-Lys3-GHRP-6 on kisspeptin-induced GH
In the first experiment, Kp-10 and Kp-10 plus D-Lys3-GHRP-6 (70 nmol/kg/bw) increased plasma GH concentrations above that of the saline-treated groups (Supplemental Fig. 4 ). There were no differences in any measure of GH levels between animals treated with Kp-10 alone and those treated with the ghrelin receptor antagonist followed by Kp-10. We repeated the study with a higher dose of D-Lys3-GHRP-6 (129 pmol/kg/ bw). When the higher dose was used, D-Lys3-GHRP-6 partially abrogated Kp-10-induced GH release (Fig. 6) . Compared with saline, ICV Kp-10 infusion increased plasma GH concentrations at 20-, 30-, and 40-minute https://academic.oup.com/endotime points. Mean GH concentrations were higher in animals treated with saline followed by Kp-10 than animals treated with D-Lys3-GHRP-6 followed by Kp-10 at 20 and 30 minutes. There was no time when mean plasma GH levels were different between groups treated with DLys3-GHRP-6 followed by saline and D-Lys3-GHRP-6 followed by Kp-10. For both AUC and peak GH levels, Kp-10 treatment elevated GH levels above those seen with saline treatment, even with D-Lys3-GHRP-6 pretreatment ( Fig. 6B and 6C ). However, AUC and peak GH levels were both attenuated in the D-Lys3-GHRP-6 pretreated animals wherein levels were significantly elevated above the saline controls but below the Kp-10 alone treated animals.
Effects of kisspeptin on plasma ghrelin
Ghrelin was measured in the samples from the experiment on the effects of central kisspeptin in animals fasted for 24 hours. There was no effect of ICV infusion of Kp-10 on plasma ghrelin concentrations in sheep (Supplemental Fig. 5 ). As an internal control for the ghrelin assay, plasma samples from ad libitum fed sheep from a separate study were also assayed and the concentrations were four to five times lower than in the fasted sheep used in this study.
Discussion
We have demonstrated that central delivery of kisspeptin will cause a robust rise in plasma GH in short-term fasted but not fed animals. Kisspeptin-induced GH was no different in animals fasted for 24 hours than those fasted for 72 hours. Pretreatment with the selective NPY Y1 receptor antagonist, BIBO 3304, blocked the effects of kisspeptin on GH, implicating NPY as an intermediary. Furthermore, immunofluorescence demonstrated that kisspeptin treatment in fasted animals increased immunoreactivity of c-Fos, a marker of cellular activation, in NPY and GHRH cells of the arcuate nucleus. Kisspeptintreated animals displayed less c-Fos in SS cells of the standard error of the mean. Symbols denote statistical significance after two-way ANOVA (P , 0.05). *Time points when the saline-followed by Kp-10-treated group was significantly different from saline alone treated group. #Differences between saline followed by Kp-10 to animals pretreated with atropine followed by Kp-10. Letters denote significant differences between groups (P , 0.05). AUC and (C) peak plasma GH concentration in saline-or kisspeptin-10-treated animals pretreated with saline or D-Lys3-GHRP-6. Data presented as the mean 6 standard error of the mean. Symbols denote statistical significance after two-way ANOVA (P , 0.05). *Time points when the saline plus kisspeptin-treated group was significantly different from saline-alone treated group. #Differences between saline followed by Kp-10 to animals pretreated with D-Lys3-GHRP-6 followed by Kp-10. Letters denote significant differences between groups (P , 0.05).
periventricular region of the hypothalamus of the same animals. Finally, blockade of systemic ghrelin release or antagonism of the ghrelin receptor totally removed or reduced the ability of kisspeptin to induce GH release, suggesting the presence of ghrelin is required for kisspeptin-induced GH in fasted animals.
Kisspeptin reliably induced GH release but only in short-term fasted animals. Moreover, this does not appear to be an effect of negative energy balance because kisspeptin-stimulated GH release was no different in animals fasted for 72 hours than those fasted for 24 hours. The profound effect of short-term food deprivation on kisspeptin's ability to induce GH secretion may explain the variability in the reports regarding kisspeptin and GH release (30) (31) (32) (33) (34) . In our previous studies on kisspeptin effects on GH release in cattle and sheep, although not a focus of those studies, the animals had varying degrees of limited food availability. Thus, when we (2, 23) demonstrated that the central delivery dependent actions of kisspeptin on GH release in cattle, the animals had free access to hay before and during treatments but were not provided feed until experiments were completed. In our previous sheep studies, food was provided the evening before but not on the morning of experiments; food was withheld until the conclusion of the experiments in midmorning (2) . In all of these cases, we demonstrated the ability of kisspeptin to induce GH secretion. Although we have yet to determine the least required duration, fasting of less than 24 hours is likely to be sufficient.
Establishing the need for short-term fasting to allow for kisspeptin-induced GH release, we then examined possible mechanisms of action. During fasting, arcuate nucleus cells, known to be involved in satiety and GH regulation, display increased NPY expression and immunoreactivity (35, 36) ; in addition, there is an increase in concentrations of NPY in the cerebrospinal fluid of fasted ewes (37) , and central infusion of NPY in the ewe results in elevated plasma GH concentrations (5, 28) . Previous work has demonstrated that kisspeptin neurons project afferents to arcuate NPY neurons (3) and NPY neurons express GPR54 (4). In addition, central administration of kisspeptin increases NPY messenger RNA (mRNA) expression in the arcuate nucleus (3) and kisspeptin treatment increases NPY release in cultured cells (4) . Our findings that central kisspeptin treatment results in increased immunofluorescence of the immediate early gene protein c-Fos immunoreactivity in NPY cells lends further support to the notion that kisspeptin stimulates NPY neurons. By pretreating animals with the selective NPY Y1 receptor antagonist, BIBO 3304, kisspeptin-induced GH was completely blocked. Taken together, our work and that of others, suggests that kisspeptin activates arcuate nucleus NPY cells, stimulating NPY release, resulting in GH secretion.
NPY does not cause GH secretion directly. The primary regulation of GH secretion from somatotropes is under reciprocal control of hypothalamic stimulation from GHRH neurons located in the arcuate nucleus and inhibition from SS neurons in the periventricular nucleus (7, 38) . During fasting, NPY expression and release increases subsequently stimulated GH release via activation of GHRH neurons and inhibition of SS neurons (6, 7, 39) . NPY fibers have been shown to be in close apposition or synapse with SS (12, 39, 40) and GHRH neurons (41) . GHRH neurons express NPY receptors (42) and central infusion of NPY results in increased GHRH in the third ventricle cerebrospinal fluid (43) . The dichotomy of NPY effects on these distinct cell groups (stimulation of GHRH/inhibition of SS) is thought to be due to NPY neurons' complex signaling through release of NPY, AgRP, norepinephrine, and g-aminobutyric acid (GABA) (44) (45) (46) . Part of the GABAergic inputs to SS neurons might originate from the NPY neurons themselves (47) (48) (49) .
Because NPY is known to control GH release, the results of these experiments with NPY suggest that kisspeptin regulates GH release through hypothalamic NPY release. The work of Park et al. (10) in NPY knockout mice supports our present findings that the metabolic state of the animal is fundamental to NPY control of GH secretion and the prerequisite that NPY controls SS and GHRH cells. Under fed conditions, GH levels in wild-type and NPY knockout animals did not differ. In wild-type mice, fasting increased GH plasma levels, increased NPY mRNA, and altered SS and GHRH expression. In fasted NPY knockout mice, GH was not elevated and GHRH or SS mRNA levels were unchanged. These observations demonstrate that NPY is not required for basal regulation of the GH axis, but is required for fasting-induced GH release and changes in SS and GHRH gene expression (10) . More specifically, the postsynaptic Y1 receptor has been shown to be responsible for the fasting-induced changes to GH release in mice (50), although presynaptic Y2 receptors have been shown to play a role in maintaining GH release in a fed state in mice. Our work supports the role of NPY Y1 receptor's role in regulating GH release in a fasted state. When NPY Y1 receptor activation was blocked, so was kisspeptininduced GH in fasted animals. Although we demonstrate a confluence of Y1 involvement in fasted sheep and mice, the physiological regulation of GH in rats and mice is different from other mammals, including sheep and humans. Unlike humans and sheep, rats and mice do not consistently demonstrate fasting-induced GH release (15, 21, 51-55) or NPY-induced GH release (5, 28, 56-58). Rodents are not an appropriate model to determine the regulation of GH release associated with fasting in the majority of animals.
FFA was elevated in the fasted animals, which demonstrated a response to fasting at the time of Kp-10 injection (Supplemental Figs. 1 and 2) (59) . FFA infusion in sheep inhibits GHRH-stimulated GH release and may reduce GH plasma concentrations by inhibiting activation of somatotropes (26, 60) . Additionally, FFA lowers GH release by decreasing the expression of the GH stimulatory receptors GHRH and GHS in baboon pituitary cell cultures (61) . Therefore, high blood FFA levels might attenuate an effect of ghrelin on GH secretion in the fasting state. Of note, when animals were pretreated with an NPY Y1 receptor antagonist, FFA levels were elevated above similarly fasted control animals (Supplemental Fig. 3 ). We do not believe elevated FFA is the mechanism by which BIBO 3304 blocked kisspeptin-induced GH. First, the lower dose of BIBO 3304 (25) reduced kisspeptin-induced GH without having an effect on FFA levels (Fig. 3) . Second, fasting for 72 hours produced a pronounced elevation in FFA without influencing the GH response to kisspeptin (Supplemental Fig. 2) . However, the role NPY and its receptor plays in FFA levels in the sheep need further investigation.
The cellular activation of NPY-ir cells and NPY Y1 receptor antagonism of kisspeptin-induced GH release implicate NPY in the response to kisspeptin but does not indicate why only fasted animals are responsive to kisspeptin. NPY expression in the arcuate increases during fasting and perhaps the increased activity of NPY neurons causes greater responsiveness to kisspeptin stimulation or perhaps the increased expression of the kisspeptin receptor in arcuate nucleus cells during fasting is important (62) . Interestingly, similar to kisspeptin, the adipose-derived hormone, leptin, has no effect on circulating concentrations of GH in fed sheep (63) , but increases circulating GH concentrations in chronically undernourished sheep (64) and in fasted heifers (65) . In addition, pretreatment of cows with leptin blocks GH release in response to NPY administered ICV (57) . However, reduced leptin levels in fasted sheep suggest leptin is not directly involved in kisspeptin-induced GH (66) .
In examining GH release associated with short-term fasting, the prominent role of the gut-derived peptide ghrelin was considered to be a potential intermediary. Ghrelin is a stimulator of GH release from somatotropes in the pituitary and alters SS and GHRH activity in the hypothalamus. Ghrelin has been shown to stimulate GHRH and NPY neurons in the mediobasal hypothalamus but not in SS cells (67) . The ghrelin receptor, GH secretagogue receptor (GHSR), is expressed in nearly all NPY neurons of the arcuate nucleus (.90%) and to a lesser degree in SS neurons in the periventricular nucleus (;20%) and GHRH cells in the arcuate nucleus (;30%) (68) (69) (70) . Ghrelin has also been shown to stimulate NPY cellular activation (71) (72) (73) , expression (74, 75) , and release (9) .
The fasting-induced rise in GH is known to involve ghrelin action, but ghrelin has been shown to be more effective in inducing GH in fed rather than fasted animals, suggesting other factors are involved during the fasted state (59, 76) . Indeed, ghrelin was elevated, along with GH in fasted animals vs fed animals before kisspeptin administration in the present studies (Fig. 1A and Supplemental Fig. 5 ). Kisspeptin induced a robust rise in GH plasma levels without affecting ghrelin levels, suggesting that ghrelin was not involved in the acute effects of kisspeptin-induced GH, but perhaps is permissive. To test this thesis, we administered atropine to fasted animals before kisspeptin treatment. Atropine competes with acetylcholine for binding to muscarinic receptors in the gastrointestinal tract. Cholinergic terminals of the vagus are found in proximity to the oxyntic glands responsible for ghrelin release from the gut (77) . Atropine has been shown to rapidly reduce ghrelin in fasting humans (78) , rats (79) , and sheep (80) . Pretreatment with atropine inhibited kisspeptin-induced GH, suggesting inhibiting ghrelin release blunts the GH response to kisspeptin. Of course, muscarinic receptors are expressed throughout the peripheral nervous system; blocking the receptor could affect multiple systems. To better assess the role of ghrelin, animals were pretreated with D-Lys3-GHRP-6, a ghrelin receptor (GHS-R1a) antagonist known to cross the blood-brain barrier and reach the hypothalamus (25) . Again, inhibiting ghrelin action reduced the GH response to kisspeptin. These results suggest elevated ghrelin in the fasted animal, either centrally generated or derived from the gut, is necessary for kisspeptin to induce GH release. Pretreatment with the GSH receptor antagonist, D-Lys3-GHRP-6, significantly reduced kisspeptin-induced GH release but did not completely block it. Considering that D-Lys3-GHRP-6 displaces a weaker affinity (IC 50 , 0.9 3 10 26 M) to the GHS receptor than ghrelin (IC 50 , 0.3 3 10 -9 M), the concentration of DLys3-GHRP-6 probably did not completely block the effects of endogenous ghrelin activation of GHS receptor. The exact mechanism by which ghrelin allows kisspeptin to act on GH release is unclear, but ghrelin and ghrelin receptor (GHSR) agonists have been shown to enhance the responsiveness of somatotropes to GHRH (81) (82) (83) (84) . Our findings suggest a neural circuit displayed in Fig. 7 . In the fed state, kisspeptin could act on NPY cells, but a low level of GPR54 expressed on NPY cells might abrogate the response. If kisspeptin were able to stimulate the NPY cells, the relatively low level of NPY in the fed state would result in limited NPY release. This would be a state in which there was reduced stimulation of GHRH cells and reduced inhibition of SS cells. During short-term fasting, ghrelin levels rise, which could increase GPR54 expression in NPY cells, NPY expression, expression/ stimulation of GHRH, and somatotrope responsiveness to GHRH. In the fasted state, ghrelin primes the circuit, allowing specifically kisspeptin to induce NPY cellular activation (increased c-Fos in NPY-ir cells). NPY, acting through the NPY Y1 receptor, stimulates GHRH (c-Fos) and inhibits SS cells (as shown by c-Fos labeling). Blocking of ghrelin release from the gut (atropine) or blocking ghrelin receptor activation (D-Lys3-GHRP-6) rapidly downregulates the gain of the system and blocks kisspeptin-induced GH.
At first consideration, these findings appear incongruent or perhaps not physiologically relevant considering prolonged food restriction leads to reduced kisspeptin production and lowered GnRH and luteinizing hormone (LH) secretion (85) . However, this is only true for prolonged fasting or food restriction. In sheep, kisspeptin expression in both the arcuate and the preoptic area region was found to be reduced in ewes made lean (86) . However, this was only examined in animals that were food restricted for a 6-month period with substantial body weight reductions, not during short-term fasting described here. During periods of metabolic stress, animals must channel energy toward survival and away from processes such as reproduction. The reproductive axis, therefore, has the capacity to respond to changing levels of metabolic cues. However, circumstances can be envisioned wherein the opposite is also true whereby the reproductive system can alter the metabolic milieu during times of short-term nutrient shortage so as not to hinder time sensitive reproductive processes such as ovulation or pregnancy just because food was not available for a short period. In these instances, kisspeptin under the control of gonadal hormones would promote further GH release during times of short-term fasting to counteract the effects of insulin and push the animal into gluconeogenesis so that perhaps ovulation and prenatal development can be unaffected by short-term food shortages. Of course, if diminished food availability is prolonged and the animal transitions into a more negative energy balance, then more pressure would be put upon the reproductive axis and kisspeptin expression would decrease and with it the effect on GH. This theory suggesting a relevant physiological link between kisspeptin and GH is supported by previous work demonstrating that GH release is induced by acute estrogen treatment or increased during times of elevated estrogen. Plasma GH concentrations are Figure 7 . Diagram of kisspeptin-induced GH release in fed vs fasted animals. In a fed state, ghrelin plasma concentration is low and arcuate nucleus NPY expression is low. In a short-term fasted state, plasma ghrelin levels rise and NPY expression increases. GPR54 expression increases in the arcuate nucleus and perhaps in NPY cells. The increased NPY and GRP54 allow for kisspeptin stimulation of NPY cells and subsequent excitation of GHRH cells and inhibition of SS cells. This leads to GHRH release into the portal vasculature of the median eminence (ME) and stimulation of somatotropes and GH release. Therefore, in a short-term fasted state, the neural circuitry involved in GH regulation is primed for kisspeptin stimulation.
elevated during estradiol-induced or spontaneous LH surge in ewes (87, 88) and humans (89) . This suggests kisspeptin can integrate GH and LH to improve reproduction and link metabolic status to fecundity. Further work will endeavor to antagonize the kisspeptin receptor during times of elevated endogenous kisspeptin.
More work is needed to determine all the factors involved in kisspeptin-induced GH release in short-term fasted animals. However, from the present findings, we demonstrate that short-term fasted animals respond to kisspeptin treatment with increased GH. The kisspeptin-induced GH is associated with increased cellular activation of NPY and GHRH-ir cells and decreased activation of SS cells. In addition, NPY Y1 receptor and GHSR activation are required for kisspeptin to induce GH release. The data support a relationship among ghrelin, kisspeptin, NPY, GHRH, SS, and GH release that would allow direct communication between the reproductive and somatotropic axes.
